Format

Send to

Choose Destination
J Am Coll Cardiol. 2013 Aug 6;62(6):496-504. doi: 10.1016/j.jacc.2013.05.022. Epub 2013 Jun 7.

Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.

Author information

1
Dipartimento Cardiovascolare, Policlinico Sant' Orsola, Bologna, Italy.

Abstract

OBJECTIVES:

The authors investigated the relative safety and efficacy of different drug-eluting stents (DES) and bare metal stents (BMS) in patients with ST-segment elevation myocardial infarction (STEMI) using a network meta-analysis.

BACKGROUND:

The relative safety of DES and BMS in patients with STEMI continues to be debated, and whether advances have been made in this regard with second-generation DES is unknown.

METHODS:

Randomized controlled trials comparing currently U.S. approved DES or DES with BMS in patients with STEMI were searched using MEDLINE, EMBASE, and Cochrane databases. Information on study design, inclusion and exclusion criteria, sample characteristics, and clinical outcomes was extracted.

RESULTS:

Twenty-two trials including 12,453 randomized patients were analyzed. At 1-year follow-up, cobalt-chromium everolimus eluting stents (CoCr-EES) were associated with significantly lower rates of cardiac death or myocardial infarction (MI) and stent thrombosis (ST) than BMS. Differences in ST were apparent as early as 30 days and were maintained for 2 years. CoCr-EES were also associated with significantly lower rates of 1-year ST than paclitaxel-eluting stents (PES). Sirolimus-eluting stents (SES) were also associated with significantly lower rates of 1-year cardiac death/myocardial infarction than BMS. CoCr-EES, PES, and SES, but not zotarolimus-eluting stents, had significantly lower rates of 1-year target vessel revascularization (TVR) than BMS, with SES also showing lower rates of TVR than PES.

CONCLUSIONS:

In patients with STEMI, steady improvements in outcomes have been realized with the evolution from BMS to first-generation and now second-generation DES, with the most favorable safety and efficacy profile thus far demonstrated with CoCr-EES.

KEYWORDS:

BMS; CoCr-EES; DES; PC-ZES; PCI; PES; PRISMA; Preferred Reporting Items for Systematic Reviews and Meta-analyses; RCT; SES; ST-segment elevation acute myocardial infarction; STEMI; StThr; TVR; bare-metal stent(s); cobalt-chromium everolimus-eluting stent(s); drug-eluting stent(s); meta-analysis; paclitaxel-eluting stent(s); percutaneous coronary intervention; phosphorylcholine-based zotarolimus-eluting stent(s); randomized controlled trial; sirolimus-eluting stent(s); stent thrombosis; target vessel revascularizations

PMID:
23747778
DOI:
10.1016/j.jacc.2013.05.022
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center